Changing the future of Oncology.
Clinical/Scientific Presentation and Publication Highlights
Dr. Wendel Naumann of The Levine Cancer Institute, Virtual Presentation of STRO-002 Antibody-Drug Conjugate (ADC) at the American Association for Cancer Research (AACR) Virtual Annual Meeting 2020
Dr. Wendel Naumann of The Levine Cancer Institute, Non-Audio Presentation of STRO-002 Antibody-Drug Conjugate (ADC) at the American Association for Cancer Research (AACR) Virtual Annual Meeting 2020Download Non-Audio Presentation CLICK HERE
Sutro Biopharma to Host Analyst and Investor Conference Call April 27, 2020 – PowerPoint Presentation
Download Presentation CLICK HERE
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
Summary of data for patients dosed at 2.9 mpk or higher in patients with heavily pre-treated ovarian cancer - 62% of patients saw a reduction in CA-125 levels of 50% or more or a normalization of CA-125 levels - 35% of patients who were evaluable for progression have...
American Association for Cancer Research (AACR) Virtual Annual Meeting 2020 – STRO-002 Abstract
STRO-002-GM1, a first in human, phase 1 Study of STRO-002, an anti-Folate Receptor alpha (FRα) Antibody Drug Conjugate (ADC), in Patients with Advanced Platinum-Resistant/Refractory Epithelial Ovarian Cancer (OC), including Fallopian Tube or Primary Peritoneal...
Sutro Biopharma to Host Conference Call on April 27, 2020, to Provide Clinical Update on its STRO-002 Antibody-Drug Conjugate
-Company to present updated STRO-002 data at AACR Virtual Annual Meeting - SOUTH SAN FRANCISCO, Calif., April 20, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise...
Sutro Biopharma to Present Updated Clinical Data for its STRO-002 Antibody-Drug Conjugate at the AACR Virtual Annual Meeting on April 27, 2020
- Company to host a conference call following the presentation - SOUTH SAN FRANCISCO, Calif., April. 13, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), today announced that the company has been invited to present updated clinical data from its STRO-002 antibody-drug...
10th Annual World ADC London 2020 – PowerPoint Presentation
To download the presentation, CLICK HERE
Sutro Biopharma to Present Innovative Cancer Therapy Approach Using Precise Tumor Targeted Immunostimulants at World ADC London
SOUTH SAN FRANCISCO, Calif., March. 4, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
Cell Free Systems Conference 2019 – Cell-Free Protein Synthesis Scale-Up and GMP Production of Protein Biotherapeutics for Clinical Trials – Poster
Cell Free Systems Conference 2019 - Poster Please click the link to enlarge image, Cell Free Systems Conference 2019
Cell Free Systems Conference 2019 – Antibody Reduction Mitigation during Harvest from Cell-Free Protein Synthesis – Poster
Cell Free Systems Conference 2019 - Poster Antibody Reduction Mitigation during Harvest from Cell-Free Protein Synthesis. Please click the link to enlarge image, Cell Free Systems Conference 2019 Poster